A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas

William B. Pearse*, Adam M. Petrich, Leo I. Gordon, Reem Karmali, Jane N. Winter, Shuo Ma, Jason B. Kaplan, Amir Behdad, Andreas Klein, Borko Jovanovic, Irene Helenowski, Sonali M. Smith, Andrew M. Evens, Barbara Pro

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Treatment strategies for post-transplant lymphoproliferative disorders (PTLD) consist of response-adapted risk-stratified methods using immunosuppression reduction, immunotherapy, and chemotherapy. We investigated the efficacy of Brentuximab vedotin given concurrently with Rituximab (BV + R) once weekly for four weeks, followed by optional consolidation, and up to one year of maintenance. Among 20 assessable patients, BV + R therapy resulted in an overall response rate of 75% (95% CI 51 to 91, p = 0.044) with 60% achieving a complete response. Median time to best response was 28 days. Two-year progression-free survival and overall survival rates were 75 and 90%, respectively. Most common severe grade 3/4 treatment-related toxicities included neutropenia (40%), hypertension (30%), infection (25%), and peripheral neuropathy (15%). BV + R is a novel and effective therapeutic strategy that achieved rapid and durable remissions in previously untreated PTLD patients; however, this treatment platform requires further modification due to the high rates of treatment-related toxicity.Key points Brentuximab vedotin + Rituximab showed ORR and CR rates of 75 and 60% in patients with immunosuppression-associated lymphoid malignancies High rates of treatment delay were attributed to treatment-related toxicity; further dosing optimization of this regimen is required.

Original languageEnglish (US)
Pages (from-to)3493-3500
Number of pages8
JournalLeukemia and Lymphoma
Volume62
Issue number14
DOIs
StatePublished - 2021

Keywords

  • Chemotherapeutic approaches
  • antibody-based immunotherapy
  • lymphoma and Hodgkin disease

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas'. Together they form a unique fingerprint.

Cite this